| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
CDK4/6; Cereblon
|
|---|---|
| ln Vitro |
T47D breast cancer cells and A375 melanoma cells were exposed to 0.3 or 1 μM XY028-140 for a whole day. Both CDK4/6 expression and activity are inhibited by XY028-140[1]. For 11 days, T47D breast cancer cells were exposed to 0.03, 0.1, 0.3, 1 or 3 μM XY028-140. Breast cancer cells' amplifiers are suspended by XY028-140 [1].
|
| References | |
| Additional Infomation |
Cyclin-dependent kinase (CDK) 4 and 6 inhibitors (CDK4/6is) are effective against metastatic breast cancer, but their efficacy is limited in most other tumor types. We found that tumors with low CDK6 expression depend on CDK4 function and are extremely sensitive to CDK4/6is. Conversely, tumor cells that co-express CDK4 and CDK6 are more dependent on CDK6 to ensure cell cycle progression. We found that in tumors where CDK6 is highly heat-sensitive and tightly bound to the HSP90-CDC37 complex, CDK4/6is and CDK4/6 degraders can effectively bind to and selectively inhibit CDK6. Conversely, because CDK4/6is and CDK4/6 degraders have weaker binding affinity to CDK6 in tumor cells expressing heat-stable CDK6, they are ineffective against these tumor cells. Therefore, we reveal the universal mechanisms of intrinsic resistance to CDK4/6i and CDK4/6i-derived degraders, and the need for novel inhibitors of CDK6 forms that are resistant to CDK4/6i and thermally stable, for use in cancer therapy. [1]
|
| Molecular Formula |
C39H40N10O7
|
|---|---|
| Molecular Weight |
760.7977
|
| Exact Mass |
760.308
|
| Elemental Analysis |
C, 61.57; H, 5.30; N, 18.41; O, 14.72
|
| CAS # |
2229974-83-6
|
| PubChem CID |
134605838
|
| Appearance |
White to yellow solid powder
|
| LogP |
2.2
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
56
|
| Complexity |
1660
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C(C(C([H])([H])[H])=O)=C(C([H])([H])[H])C2=C([H])N=C(N([H])C3C([H])=C([H])C(=C([H])N=3)N3C([H])([H])C([H])([H])N(C(C([H])([H])N([H])C4=C([H])C([H])=C([H])C5C(N(C(C=54)=O)C4([H])C(N([H])C(C([H])([H])C4([H])[H])=O)=O)=O)=O)C([H])([H])C3([H])[H])N=C2N1C1([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H]
|
| InChi Key |
IWFNIKIERKCKFZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C39H40N10O7/c1-21-26-19-42-39(45-34(26)48(23-6-3-4-7-23)37(55)32(21)22(2)50)43-29-12-10-24(18-41-29)46-14-16-47(17-15-46)31(52)20-40-27-9-5-8-25-33(27)38(56)49(36(25)54)28-11-13-30(51)44-35(28)53/h5,8-10,12,18-19,23,28,40H,3-4,6-7,11,13-17,20H2,1-2H3,(H,44,51,53)(H,41,42,43,45)
|
| Chemical Name |
4-[[2-[4-[6-[(6-acetyl-8-cyclopentyl-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]pyridin-3-yl]piperazin-1-yl]-2-oxoethyl]amino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
|
| Synonyms |
XY028-140; 2229974-83-6; MS140; 4-((2-(4-(6-((6-acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)-2-oxoethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 4-((2-(4-(6-((6-acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido(2,3-d)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)-2-oxoethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; orb1303928; SCHEMBL20260469; SCHEMBL29388789;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5.56 mg/mL (~7.31 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 0.56 mg/mL (0.74 mM) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.6 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3144 mL | 6.5720 mL | 13.1441 mL | |
| 5 mM | 0.2629 mL | 1.3144 mL | 2.6288 mL | |
| 10 mM | 0.1314 mL | 0.6572 mL | 1.3144 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
